PROVIDENCE – Lyora Therapeutics, a Providence-based biotech company specializing in the treatment of hereditary retinal diseases, has officially launched publicly after operating in stealth for the past year. Lyora’s portfolio currently includes three treatments under development for genetic retinal diseases that cause vision loss and potential blindness for retinitis pigmentosa, Usher syndrome and Leber Congenital Amaurosis, according to the firm’s
Already a Subscriber? Log in
To Continue Reading This Article
Become a Providence Business News subscriber and get immediate access to all of our premier content and much more.Learn More and Become a Subscriber
